Sean Patrick Cleary

Sean Patrick Cleary

Auto-generated profile, based on publicly available information

Sean Patrick Cleary

University of Toronto

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015
Verified
Journal Article
Closed access
GWGo Wakabayashi
Go Wakabayashi
DCDaniel Cherqui
Daniel Cherqui
David GellerDavid Geller
David Geller
JBJoseph F Buell
Joseph F Buell
HKHironori Kaneko
Hironori Kaneko
SSSteven M Strasberg
Steven M Strasberg
The use of laparoscopy for liver surgery is increasing rapidly. The Second International Consensus Conference on Laparoscopic Liver Resections (LLR) was held in Morioka, Japan, from October 4 to 6, 2014 to evaluate the current status of laparoscopic liver surgery and to provide recommendations to aid its future development. Seventeen questions were addressed. The first 7 questions focused on outcomes that reflect the benefits and risks of LLR. These questions were addressed using the Zurich-Danish consensus conference model in which the literature and expert opinion were weighed by a 9-member jury, who evaluated LLR outcomes using GRADE and a list of comparators. The jury also graded LLRs by the Balliol Classification of IDEAL. The jury concluded that MINOR LLRs had become standard practice (IDEAL 3) and that MAJOR liver resections were still innovative procedures in the exploration phase (IDEAL 2b). Continued cautious introduction of MAJOR LLRs was recommended. All of the evidence available for scrutiny was of LOW quality by GRADE, which prompted the recommendation for higher quality evaluative studies. The last 10 questions focused on technical questions and the recommendations were based on literature review and expert panel opinion. Recommendations were made regarding preoperative evaluation, bleeding controls, transection methods, anatomic approaches, and equipment. Both experts and jury recognized the need for a formal structure of education for those interested in performing major laparoscopic LLR because of the steep learning curve.

12 October 2016 in Nature
Verified
Journal Article
Closed access
PDF file
FNFaiyaz Notta
Faiyaz Notta
MCMichelle Chan-Seng-Yue
Michelle Chan-Seng-Yue
MLMathieu Lemire
Mathieu Lemire
YLYilong Li
Yilong Li
GWGavin W. Wilson
Gavin W. Wilson
SGSteven Gallinger
Steven Gallinger

29 March 2019 in Annals of Surgery
Verified
Journal Article
Open access
MTMark J. Truty
Mark J. Truty
MKMichael L. Kendrick
Michael L. Kendrick
DNDavid M. Nagorney
David M. Nagorney
RSRory L. Smoot
Rory L. Smoot
SCSean P. Cleary
Sean P. Cleary
AGAxel F. Grothey
Axel F. Grothey
Objective: To identify predictive factors associated with operative morbidity, mortality, and survival outcomes in patients with borderline resectable (BR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC) undergoing total neoadjuvant therapy (TNT). Background: The optimal preoperative treatment sequencing for BR/LA PDA is unknown. TNT, or systemic chemotherapy followed by chemoradiation (CRT), addresses both occult metastases and positive margin risks and thus is a potentially optimal strategy; however, factors predictive of perioperative and survival outcomes are currently undefined. Methods: We reviewed our experience in BR/LA patients undergoing resection from 2010 to 2017 following TNT assessing operative morbidity, mortality, and survival in order to define outcome predictors and response endpoints. Results: One hundred ninety-four patients underwent resection after TNT, including 123 (63%) BR and 71 (37%) LA PDAC. FOLFIRINOX or gemcitabine along with nab-paclitaxel were used in 165 (85%) and 65 (34%) patients, with 36 (19%) requiring chemotherapeutic switch before long-course CRT and subsequent resection. Radiologic anatomical downstaging was uncommon (28%). En bloc venous and/or arterial resection was required in 125 (65%) patients with 94% of patients achieving R0 margins. The 90-day major morbidity and mortality was 36% and 6.7%, respectively. Excluding operative mortalities, the median, 1-year, 2-year, and 3-year recurrence-free survival (RFS) [overall survival (OS)] rates were 23.5 (58.8) months, 65 (96)%, 48 (78)%, and 32 (62)%, respectively. Radiologic downstaging, vascular resection, and chemotherapy regimen/switch were not associated with survival. Only 3 factors independently associated with prolonged survival, including extended duration (≥6 cycles) chemotherapy, optimal post-chemotherapy CA19-9 response, and major pathologic response. Patients achieving all 3 factors had superior survival outcomes with a survival detriment for each failing factor. In a subset of patients with interval metabolic (PET) imaging after initial chemotherapy, complete metabolic response highly correlated with major pathologic response. Conclusion: Our TNT experience in resected BR/LA PDAC revealed high negative margin rates despite low radiologic downstaging. Extended duration chemotherapy with associated biochemical and pathologic responses highly predicted postoperative survival. Potential modifications of initial chemotherapy treatment include extending cycle duration to normalize CA19-9 or achieve complete metabolic response, or consideration of chemotherapeutic switch in order to achieve these factors may improve survival before moving forward with CRT and subsequent resection.

1 March 2007 in Surgery
Verified
Journal Article
Closed access
SSShimul A. Shah
Shimul A. Shah
SCSean P. Cleary
Sean P. Cleary
AWAlice C. Wei
Alice C. Wei
IYIlun Yang
Ilun Yang
BTBryce R. Taylor
Bryce R. Taylor
SGSteven Gallinger
Steven Gallinger

30 June 2016 in Hepatology
Verified
Journal Article
Closed access
PDF file
GSGonzalo Sapisochin
Gonzalo Sapisochin
NGNicolas Goldaracena
Nicolas Goldaracena
JLJerome M. Laurence
Jerome M. Laurence
MDMartin Dib
Martin Dib
ABAndrew Barbas
Andrew Barbas
DGDavid R. Grant
David R. Grant

31 May 2013 in Hepatology
Verified
Journal Article
Open access
PDF file
SCSean P. Cleary
Sean P. Cleary
WJWilliam R. Jeck
William R. Jeck
XZXiaobei Zhao
Xiaobei Zhao
KCKui Chen
Kui Chen
SSSara R. Selitsky
Sara R. Selitsky
DCDerek Y. Chiang
Derek Y. Chiang
Genetic alterations in specific driver genes lead to disruption of cellular pathways and are critical events in the instigation and progression of hepatocellular carcinoma (HCC). As a prerequisite for individualized cancer treatment, we sought to characterize the landscape of recurrent somatic mutations in HCC. We performed whole-exome sequencing on 87 HCCs and matched normal adjacent tissues to an average coverage of 59×. The overall mutation rate was roughly two mutations per Mb, with a median of 45 nonsynonymous mutations that altered the amino acid sequence (range, 2-381). We found recurrent mutations in several genes with high transcript levels: TP53 (18%); CTNNB1 (10%); KEAP1 (8%); C16orf62 (8%); MLL4 (7%); and RAC2 (5%). Significantly affected gene families include the nucleotide-binding domain and leucine-rich repeat-containing family, calcium channel subunits, and histone methyltransferases. In particular, the MLL family of methyltransferases for histone H3 lysine 4 were mutated in 20% of tumors. Conclusion: The NFE2L2 - KEAP1 and MLL pathways are recurrently mutated in multiple cohorts of HCC. (Hepatology 2013;58:1693–1702)